Effects of T-bet B Cells in Persistent Virus Control After Discontinuance of NAs in CHB Patients
NCT ID: NCT06029634
Last Updated: 2023-09-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
45 participants
OBSERVATIONAL
2020-07-01
2023-08-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Real-World Study of Antiviral Therapy in Children With Chronic Hepatitis B
NCT06926647
Off Treatment Durability in Chronic Hepatitis B With Good Immune Control
NCT02738554
Early Response to Interferon Combined Short-Term Nucleoside Analogue Therapy in HBeAg(+) Chronic Hepatitis B
NCT00860626
Sustained Off-treatment Response After HBeAg Loss in Chronic Hepatitis B Patients Treated With Nucleos(t)Ide Analogues
NCT01911156
Efficacies of Entecavir Add on HBeAg Negative Patients With HBV DNA Positive During Peginterferon Alpha 2a Treatment
NCT02365402
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
virologic breakthrough
CHB patients withdraw NAs with virologic breakthrough
T-bet B cell
The frequency, function, and phenotype of T-bet B cells was tested
virologic response
CHB patients withdraw NAs with virologic response
T-bet B cell
The frequency, function, and phenotype of T-bet B cells was tested
healthy group
The healthy (non-HBV infected) group completed a standard HBsAg vaccination scheduled before entering the study
T-bet B cell
The frequency, function, and phenotype of T-bet B cells was tested
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
T-bet B cell
The frequency, function, and phenotype of T-bet B cells was tested
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
70 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Changhai Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
XueSong Liang
Dr
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Xuesong Liang, DR
Role: PRINCIPAL_INVESTIGATOR
Chaihai hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Changhai hospital
Shanghai, , China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
T-bet B
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.